Boston Scientificの空売り状況は、投資家がBoston Scientificの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Boston Scientific (NYSE:BSX) 株価情報, 空売り情報

BOSTON SCIENTIFIC CORP

Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Boston Scientific Corporation Common Stock

Boston Scientific Corp

Basilisk - United States Dollar

BELO SUN MINING CORP ORD by Belo Sun Mining Corp.

Belo Sun Mining Corp

President Donald Trump announced tougher-than-anticipated tariffs on Wednesday, but there are some <a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noreferrer noopener">notable exemptions</a>.
Trump excluded pharmaceuticals from the new tariffs, likely a relief for the industry under pressure following his prior comments suggesting a 25% tariff <a href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" target="_blank" rel="noreferrer noopener">on pharmaceutical imports</a>. 
&#8220;The United States can no longer produce enough antibiotics to treat our sick,&#8221; Trump said Wednesday. &#8220;We have a tremendous problem, we have to go to foreign countries to treat our sick. If anything ever happened from a war standpoint, we wouldn&#8217;t be able to do it.&#8221;
The biopharma industry has historically been shielded from tariffs, including during Trump's first term. Investors had feared global tariffs could disrupt the sector, given its significant manufacturing presence in Europe. The Morningstar <a target="_blank" href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" rel="noreferrer noopener">report</a> says that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have resulted in a $20 billion cost to the industry, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44592073/tariffs-could-shake-building-industry-homebuilders-plumbing-flooring-face-rising-costs" rel="noreferrer noopener">Tariffs Could Shake Building Industry: Homebuilders, Plumbing, Flooring Face Rising Costs</a>
Per the Morningstar report on Thursday, a future global tariff on pharmaceuticals remains a risk despite the exemption, potentially pressuring gross margins and long-term tax rates. Companies may need to adjust their manufacturing strategies, though large-cap biopharma firms are expected to maintain strong economic positions. Tariffs could drive near-term margin pressures and lead to long-term U.S. manufacturing investments.
However, new facilities would take years to gain approval, especially with ongoing FDA staff <a href="https://www.benzinga.com/25/04/44634464/despite-headwinds-biotech-sell-off-could-offer-buying-opportunity-bofa" target="_blank" rel="noreferrer noopener">reductions affecting inspections</a>. If U.S. manufacturing increases, corporate tax rates could rise closer to the current 21% rate &#8211; a level Trump aims to maintain through the Republican-controlled Congress.
However, the medical device industry has not been spared, with diabetes device makers appearing to be the hardest hit.
Diabetes device manufacturers, including Dexcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), Insulet Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NYSE">PODD</a>) and Tandem Diabetes Care, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) are among the most affected.
Larger cardiac and orthopedic device makers, such as Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) and Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) have seen minimal share movement and are expected to shift manufacturing to mitigate tariff effects.
The report <a href="https://www.morningstar.com/stocks/medical-device-industry-swept-up-tariffs-diabetes-device-makers-bear-brunt" target="_blank" rel="noreferrer noopener">notes</a> that among diabetes device makers, Tandem Diabetes appears particularly vulnerable due to its reliance on foreign components and manufacturing, limiting its ability to shift production.
The sector could face further challenges if European competitors, such as Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) and Ypsomed, gain an advantage or if Europe imposes reciprocal tariffs, intensifying competitive pressures.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44647281/fda-approves-amgens-uplizna-as-first-drug-for-chronic-immune-mediated-fibroinflammatory-disorder" target="_blank" rel="noreferrer noopener">FDA Approves Amgen&#8217;s Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder</a></li>
</ul>
Photo: Shutterstock

Biotech

Government

Large Cap

News

Health Care

General

DXCM

PODD

RHHBY

TNDM

Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry

Looking into the current session, Boston Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) shares are trading at $96.89, after a 3.16% drop. Over the past month, the stock fell by 1.95%, but over the past year, it actually spiked by 44.16%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1743696034_0.png" alt="Past Year Chart" />

<h3>Boston Scientific P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Boston Scientific has a lower P/E than the aggregate P/E of 81.19 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743696034_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Boston Scientific

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>), adding that he likes the <a href="https://www.benzinga.com/quote/GRAL">stock a lot.</a>
Supporting his view, Morgan Stanley analyst Tejas Savant, on March 18, raised the price target on the stock from $16 to $20.
&#8220;That' like a dice roll,&#8221; Cramer said when asked about Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>). &#8220;That's a bridge too far for me.&#8221;
On the earnings front, Turkcell, on Feb. 27, posted an FY net profit of 23.52 billion Lira versus a year-ago profit of 18.13 billion Lira.
When asked about Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>), he said, &#8220;I'm going to say buy half right now, and then if it breaks down below 53, then you can buy more.&#8221;
Keefe, Bruyette &amp; Woods analyst Vasundhara Govil, on March 18, upgraded Block from Market Perform to Outperform but lowered the price target from $87 to $80.
Healthpeak Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) is a &#8220;reasonable&#8221; REIT, Cramer said.
On Feb. 28, Scotiabank analyst Nicholas Yulico maintained Healthpeak Properties with a Sector Outperform and lowered the price target from $24 to $23.
The Mad Money host said Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is doing &#8220;very, very well.&#8221;
As per the recent news, NTT DATA partnered with Rubrik on Monday for cybersecurity ransomware protection.
Cramer said Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is a hold and prefers Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) to Edwards Lifesciences.
On the earnings front, Edwards Lifesciences, on Feb. 11, posted better-than-expected quarterly earnings.
&#8220;We have to wait another quarter,&#8221; Cramer said when asked about Shake Shack Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>).
Wells Fargo analyst Anthony Trainor, on Wednesday, initiated coverage on Shake Shack with an Equal-Weight rating and announced a price target of $95.
TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) is an &#8220;interesting&#8221; company, Cramer said. &#8220;I'm not going to necessarily recommend it right here.&#8221;
Needham analyst Mike Matson reiterated TransMedics Group with a Hold rating on Wednesday.
&#8220;It's never been this cheap that I can recall,&#8221; Cramer said when asked about Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>). &#8220;Here's the problem, it's a data center stock.&#8221;
On March 5, UBS analyst David Vogt upgraded Arista Networks from Neutral to Buy and raised the price target from $112 to $115.
Price Action:
Turkcell Iletisim Hizmetleri shares fell 2.3% to settle at $6.08 on Thursday.
GRAIL shares gained 0.7% to close at $28.58 during the session.
Arista Networks&#8217; shares fell 3.3% to settle at $78.96.
Shake Shack shares rose 0.3% to settle at $93.62.
TransMedics Group shares gained 0.2% to close at $70.44.
Rubrik shares fell 3.8% to settle at $66.00.
Edwards Lifesciences&#8217; shares rose 0.1% to close at $71.19.
Block shares fell 3.5% to settle at $56.99 on Thursday.
Healthpeak Properties shares fell 0.4% to close at $20.22.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44534563/netflix-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades">Netflix, Vertex Pharmaceuticals And More On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>
Photo: Shutterstock

Mid Cap

Media

ANET

GRAL

RBRK

SHAK

TMDX

Jim Cramer: Healthpeak Properties Is A 'Reasonable' REIT, Recommends Buying This Health Care Stock

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 5 years by 8.22% on an annualized basis producing an average annual return of 25.31%. Currently, Boston Scientific has a market capitalization of $149.09 billion. 
Buying $100 In BSX: If an investor had bought $100 of BSX stock 5 years ago, it would be worth $318.58 today based on a price of $100.80 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743111907_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Boston Scientific 5 Years Ago Would Be Worth This Much Today

Last week,&nbsp;U.S. President&nbsp;Donald Trump vowed to impose a 25% tariff on imported goods from Mexico and Canada and to double tariffs on&nbsp;<a target="_blank" href="https://www.benzinga.com/news/global/25/02/44010093/trumps-plan-for-canada-mexico-china-tariffs-to-start-march-4-could-shake-stock-market" rel="noreferrer noopener">those from China to 20%</a>.
China responded to Trump&#8217;s recent tariff hikes by placing its own tariffs on certain U.S. goods, sanctioning American companies, and planning to file a complaint with&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/25/03/44117288/after-china-mexico-to-hit-back-against-trumps-tariffs-raising-trade-war-risks" rel="noreferrer noopener">the World Trade Organization</a>.
China also banned imports of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">genetic sequencers</a> from&nbsp;Illumina Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43706143/why-is-ge-healthcare-stock-trading-higher-on-thursday" rel="noreferrer noopener">Why Is GE HealthCare Stock Trading Soaring On Thursday?</a>
Goldman Sachs has grown more confident that end markets are stabilizing and set for a recovery in 2025, despite ongoing policy and tariff uncertainties. Rising demand and increased stimulus are helping ease market bottlenecks.
Following a visit to China, Goldman Sachs analysts see capital equipment markets at a turning point and write that innovation remains a key advantage.
They are also optimistic about GE Healthcare Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) and Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) in the region.
While Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) offers unique technology, economic constraints, and national quotas may limit its growth. Meanwhile, local competition is expanding quickly, but Goldman Sachs sees limited impact due to a lack of technological differentiation. As a result, analyst David Roman upgraded GE Healthcare stock from Neutral to Buy, raising the <a target="_blank" href="https://editorial.benzinga.com/wp-admin/post.php?post=819159&amp;action=edit" rel="noreferrer noopener">price target from $85 to $100</a>.
The analyst has a balanced view on GE Healthcare with stable 4-5% growth in the base business (ex-China), offset by sustained headwinds in the China business (~14% of sales), which would yield top-line growth below consensus and the company&#8217;s medium targets of 4-6% organic revenue growth.
The forecast increase is due to stabilizing trends in China. The analyst expects China sales to return to 2023 levels by 2026, unlike the previous forecast, which did not anticipate a rebound through 2028.
Price Action: GEHC stock is up 0.45% at $85.74&nbsp;at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44251506/inuvo-is-better-aligned-with-consumer-demand-for-privacy-new-regulations-analyst" target="_blank" rel="noreferrer noopener">Inuvo Is Better Aligned With Consumer Demand For Privacy, New Regulations: Analyst</a></li>
</ul>
Photo by PixelBiss via Shutterstock

Analyst Color

Upgrades

Analyst Ratings

GEHC

ILMN

ISRG

Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 5 years by 9.97% on an annualized basis producing an average annual return of 28.2%. Currently, Boston Scientific has a market capitalization of $140.77 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 5 years ago, it would be worth $2,951.28 today based on a price of $95.39 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741706110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Watching Boston Scientific Corp; Hearing Investor Business Daily SwingTrader Buys Stock

In the preceding three months, 17 analysts have released ratings for Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Boston Scientific, presenting an average target of $114.88, a high estimate of $130.00, and a low estimate of $100.00. Surpassing the previous average price target of $103.06, the current average has increased by 11.47%.
<img src="https://www.benzinga.com/files/images/story/2025/1741024862_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Boston Scientific by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$122.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$116.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$122.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$119.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$98.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Boston Scientific compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Boston Scientific's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BSX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Boston Scientific analyst ratings.</a>
<h2>Get to Know Boston Scientific Better</h2>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
<h3>Financial Insights: Boston Scientific</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Boston Scientific showcased positive performance, achieving a revenue growth rate of 22.44% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Boston Scientific's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.39% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.66%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Boston Scientific's ROA stands out, surpassing industry averages. With an impressive ROA of 1.46%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.51.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 17 Analysts Discuss Boston Scientific Stock

On Monday, Boston Scientific Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) agreed to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44073224/boston-scientific-announces-agreement-to-acquire-sonivie-ltd" rel="noreferrer noopener">Intravascular Ultrasound System</a>.
Boston Scientific currently holds an equity stake of approximately 10%. Therefore, the transaction consists of an upfront payment of approximately&nbsp;$360 million&nbsp;for the 90% and up to&nbsp;$180 million&nbsp;upon achievement of a regulatory milestone.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43494194/boston-scientific-clocks-22-jump-in-q4-sales-on-strong-heart-devices-profit-and-guidance-exceeds-expectations" rel="noreferrer noopener">Boston Scientific Clocks 22% Jump In Q4 Sales On Strong Heart Devices, Profit And Guidance Exceeds Expectations</a>
On a 100% basis, the transaction price consists of $400&nbsp;million upfront and up to&nbsp;$200 million upon achievement of a regulatory milestone.
An investigational TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension.
Boston Scientific anticipates completing the transaction in the first half of 2025.
The company expects the transaction to be slightly dilutive to adjusted EPS in 2025.
The TIVUS system is designed to perform RDN that can help reduce activity in the kidney&#8217;s renal nerves and serve as an alternative or adjunctive therapy to these medications to help regulate blood pressure.
Compared to radiofrequency energy, ultrasound energy has the potential to penetrate the tissue more deeply, which may result in faster procedures with effective nerve ablation.
The catheter-based TIVUS system generates precise ultrasound energy that passes through the blood and into renal arteries, supplying blood to the kidneys without anchoring to the artery wall, allowing continual blood flow to cool the treatment area.
This energy is designed to heat and ablate the bundles of nerves outside the arteries, stopping their ability to pass signals and reducing the sympathetic hormones released from the nerves. As a result, the blood vessels relax, and the pressure within them is reduced.
Last year, SoniVie announced efficacy data from an IDE pilot trial of the TIVUS system in the U.S. and&nbsp;Israel. The company recently initiated the THRIVE global IDE pivotal trial of the device.
Price Action: BSX stock is up 0.97% at $104.88 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/44053788/alkami-growth-accelerates-with-mantl-deal-boosting-digital-banking-and-cross-sell-potential-analyst-says" target="_blank" rel="noreferrer noopener">Alkami Growth Accelerates With MANTL Deal, Boosts Digital Banking And Cross-Sell Potential: Analyst</a></li>
</ul>
Photo: Shutterstock

Boston Scientific To Acquire SoniVie For $400 Million, Expanding Hypertension Treatment Portfolio

Needham analyst Mike Matson reiterates Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Boston Scientificto Hold

An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension.

Boston Scientific Agreed To Acquire SoniVie, A Privately Held Medical Device Company That Has Developed The Tivus Intravascular Ultrasound System For Approximately $360M And Up To $180M Upon Achievement Of A Regulatory Milestone

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 10 years by 8.74% on an annualized basis producing an average annual return of 19.64%. Currently, Boston Scientific has a market capitalization of $148.32 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 10 years ago, it would be worth $5,903.87 today based on a price of $100.50 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740522627_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today

Boston Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) short percent of float has fallen 27.55% since its last report. The company recently reported that it has 10.45 million shares sold short, which is 0.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.65 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Boston Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740407417_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Boston Scientific has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Boston Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Boston Scientific's peer group average for short interest as a percentage of float is 3.93%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Boston Scientific?

Reported Friday, Boston Scientific Prices €1.5B In Senior Notes, Consisting Of €850M 3.000% Due 2031 And €650M 3.250% Due 2034

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/pacemaker-recall-boston-scientific-corporation-recalls-accolade-pacemaker-devices-due-manufacturing#:~:text=Boston%20Scientific%20Corporation%20is%20recalling,during%20critical%20device%20component%20failures" title="https://www.fda.gov/medical-devices/medical-device-recalls/pacemaker-recall-boston-scientific-corporation-recalls-accolade-pacemaker-devices-due-manufacturing#:~:text=Boston%20Scientific%20Corporation%20is%20recalling,during%20critical%20device%20component%20failures">https://www.fda.gov/medical-devices/medical-device-recalls/pacemaker-recall-boston-scientific-corporation-recalls-accolade-pacemaker-devices-due-manufacturing#:~:text=Boston%20Scientific%20Corporation%20is%20recalling,during%20critical%20device%20component%20failures</a>.

'Pacemaker Recall: Boston Scientific Corporation Recalls Accolade Pacemaker Devices Due to a Manufacturing Issue That May Lead to Early Device Replacement' - FDA

Making a noteworthy insider sell on February 13, EDWARD LUDWIG, Director at Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), is reported in the latest SEC filing.
What Happened: After conducting a thorough analysis, LUDWIG sold 12,000 shares of Boston Scientific. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000885725/000122520825001594//Archives/edgar/data/885725/000122520825001594/0001225208-25-001594-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total transaction value is $1,265,815.
The latest market snapshot at Thursday morning reveals Boston Scientific shares down by 0.0%, trading at $105.77.
<h3>Get to Know Boston Scientific Better</h3>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
<h3>Breaking Down Boston Scientific's Financial Performance</h3>
Revenue Growth: Boston Scientific's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 19.34%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 68.83%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Boston Scientific's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.32.
</li>
</ul>
Debt Management: Boston Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.54.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 84.62, Boston Scientific's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 9.38, Boston Scientific's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boston Scientific's EV/EBITDA ratio of 47.82 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000885725">Check Out The Full List Of Boston Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Sell Alert: EDWARD LUDWIG Cashes Out $1.27M In Boston Scientific Stock

Stifel analyst Rick Wise maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $115 to $120.

Price Target

Stifel Maintains Buy on Boston Scientific, Raises Price Target to $120

Barclays analyst Matt Miksic maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $111 to $118.

Barclays Maintains Overweight on Boston Scientific, Raises Price Target to $118

UBS analyst Danielle Antalffy maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $105 to $130.

UBS Maintains Buy on Boston Scientific, Raises Price Target to $130

Raymond James analyst Jayson Bedford maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Strong Buy and raises the price target from $119 to $122.

Raymond James Maintains Strong Buy on Boston Scientific, Raises Price Target to $122

Press Releases

Biotech Breakthroughs: Sana Biotechnology (NASDAQ: SANA) Type 1 Diabetes, CS Diagnostics (OTCQB: CSDX) Cancer Therapy – CURR, TPET, PRSO, PNPN.V, EONR – Plus More Stocks Under $2 Inside See Now!

Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation

Earnings

Boston Scientific announces results for fourth quarter and full year 2024

Boston Scientific to participate in TD Cowen's 45th Annual Health Care Conference

UroGen Pharma Ltd. (NASDAQ: URGN), CS Diagnostics Corp. (OTCQB: CSDX) and Boston Scientific (NYSE: BSX) Advancing Cancer Treatment Technology – More Stocks Inside

Comments

Boston Scientific

空売り

Boston Scientific (NYSE:BSX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル